Korean Society for Bone and Mineral Research Task Force Report: Perspectives on Intermittent High-dose Vitamin D Supplementation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최한석 | - |
dc.contributor.author | 민용기 | - |
dc.contributor.author | 변동원 | - |
dc.contributor.author | 한명훈 | - |
dc.contributor.author | 김경민 | - |
dc.contributor.author | 김범준 | - |
dc.contributor.author | 오기원 | - |
dc.date.accessioned | 2021-08-11T15:44:26Z | - |
dc.date.available | 2021-08-11T15:44:26Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 2287-6375 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/8162 | - |
dc.description.abstract | An adequate supply of vitamin D is considered necessary for osteoporosis management and fracture prevention. Intermittent high-dose vitamin D supplementation is an effective and convenient way to achieve and maintain sufficient vitamin D status. However, the long-term effectiveness of supplementation for preventing falls and fractures is unclear, and some deleterious effects of such treatments have been reported. Concerning these issues, the Korean Society for Bone and Mineral Research task force team reviewed previous clinical trials and provided the following perspectives based on current evidence: 1) An adequate supply of vitamin D is necessary for preventing falls and fractures in postmenopausal women and men older than 50 years. An oral intake of 800 to 1,000 IU/day of vitamin D is generally recommended. 2) Care should be taken concerning the routine use of intermittent high-dose vitamin D, as large-scale clinical trials showed increased risk of falls or fractures after high-dose vitamin D administration. Intermittent high-dose vitamin D supplementation is recommendable only in cases of malabsorption or when oral administration is not suitable. 3) Monitoring of the serum level of 25-hydroxy-vitamin D (25[OH]D) is advisable, especially when intermittent high-dose vitamin D is used for supplementation. The task force team suggests that a serum 25(OH)D level of >20 ng/mL is generally appropriate for the prevention of osteoporosis, and that a serum 25(OH)D level of >30 ng/mL is probably helpful both for the management of osteoporosis and the prevention of fractures and falls. However, serum 25(OH)D level >50 ng/mL (this value can vary depending on the measurement method used) is unnecessary and may be undesirable. These perspectives are relevant for the management of osteoporosis, falls, or fractures. Other metabolic bone diseases or non-skeletal disorders are not within the scope of these perspectives. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한골대사학회 | - |
dc.title | Korean Society for Bone and Mineral Research Task Force Report: Perspectives on Intermittent High-dose Vitamin D Supplementation | - |
dc.title.alternative | Korean Society for Bone and Mineral Research Task Force Report: Perspectives on Intermittent High-dose Vitamin D Supplementation | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 변동원 | - |
dc.identifier.doi | 10.11005/jbm.2017.24.3.141 | - |
dc.identifier.bibliographicCitation | 대한골대사학회지, v.24, no.3, pp.141 - 145 | - |
dc.relation.isPartOf | 대한골대사학회지 | - |
dc.citation.title | 대한골대사학회지 | - |
dc.citation.volume | 24 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 141 | - |
dc.citation.endPage | 145 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART002258057 | - |
dc.description.journalClass | 2 | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Vitamin D | - |
dc.subject.keywordAuthor | Osteoporosis | - |
dc.subject.keywordAuthor | Fracture | - |
dc.subject.keywordAuthor | Fall | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.